Press releaseGlobe Newswire
Jade Biosciences
JBIO · NASDAQ
$14.86+$1.03 (+7.45%)TodayMarket closed ·
Prev close $13.83
Latest news
- Press releaseGlobe Newswire
Jade Biosciences to Participate in Upcoming Conferences
- Press releaseGlobe Newswire
Jade Biosciences Reports Second Quarter 2026 Financial Results and Provides Corporate Update
- Press releaseGlobe Newswire
Jade Biosciences Announces Appointment of Mark Eisner, M.D., M.P.H., to Board of Directors
- NewsRishabh Mishra
Stock Market Today: S&P 500, Dow, Nasdaq Futures Fall As House Challenges Trump's Military Authority— Broadcom, CrowdStrike In Focus (UPDATED)
- NewsAvi Kapoor
Ciena, Docusign And 3 Stocks To Watch Heading Into Thursday
- NewsVandana Singh
Why Is Jade Biosciences Stock Trading Lower On Monday?
- NewsAvi Kapoor
Taylor Morrison Home Surges On Berkshire Hathaway Acquisition, Joins Elmet Group And Other Big Stocks Moving Higher In Monday's Session
- News
jade Biosciences Announces Interim Results From Its Phase 1 Trial Evaluating JADE101, A Novel, Investigational AntI-A Proliferation-Inducing Ligand Monoclonal Antibody In Development For The Treatment Of Immunoglobulin A Nephropathyl; JADE101 Showed Favorable Safety Profile And Well-Tolerated Across All Evaluated Subcutaneous Dose Levels
- Press releaseGlobe Newswire
Jade Biosciences Announces Positive Interim Phase 1 Results for JADE101 Demonstrating Potential Best-in-Class Profile and Every-12-Week Dosing in IgA Nephropathy
- Press releaseGlobe Newswire
Jade Biosciences to Host Conference Call and Webcast on June 1, 2026, at 8:00 a.m. ET to Discuss Interim Phase 1 Healthy Volunteer Results for JADE101, a Novel, Potentially Best-in-Class Anti-APRIL Monoclonal Antibody in Development for IgA Nephropathy
- Press releaseGlobe Newswire
Jade Biosciences Announces First Participant Dosed in First-in-Human Phase 1 Clinical Trial of JADE201, a Novel Half-Life Extended Afucosylated Anti-BAFF Receptor Monoclonal Antibody
- Press releaseGlobe Newswire
Jade Biosciences Announces First Participant Dosed in Phase 2 JUNIPER Clinical Trial of JADE101 in IgA Nephropathy
- NewsAvi Kapoor
This Applied Digital Begins Coverage On A Bullish Note; Here Are Top 4 Initiations For Wednesday
- NewsAvi Kapoor
Why Intelligent Bio Solutions Shares Are Trading Lower By Around 20%? Here Are Other Stocks Moving In Friday's Mid-Day Session
- NewsAvi Kapoor
Jazz Pharmaceuticals, Sigma Lithium, Zymeworks And Other Big Stocks Moving Higher On Monday
- NewsAvi Kapoor
Abbott Laboratories Issues Weak Earnings Forecast, Joins MP Materials And Other Big Stocks Moving Lower In Thursday's Pre-Market Session
- NewsAvi Kapoor
Expedia, Wolfspeed, HubSpot And Other Big Stocks Moving Lower In Friday's Pre-Market Session
- News
12 Health Care Stocks Moving In Friday's Pre-Market Session
- NewsAvi Kapoor
Why Pinterest Shares Are Trading Higher By 13%; Here Are 20 Stocks Moving Premarket
Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.